PBMs will have to display TrumpRx drug prices, while Bristol's Zenbexus gains accelerated approval and Novartis wins a UK patent fight over Entresto, in a biotech news roundup.
The FDA rejected a radiopharmaceutical therapy due to manufacturing issues, blocking a potential competitor to Novartis.
FDA rejects a radiopharmaceutical therapy over manufacturing issues, removing a potential competitor to Novartis.
The TIGIT drug program hype collapsed after billions spent and multiple late-stage failures across Roche, Merck, Beigene, GSK/iTeos, and others, with regulators granting and later debunking designations, culminating in a broad industry shift away from Fc-active/ Fc-silent TIGIT strategies and a surviving asset only in AstraZeneca’s rilvegostomig.
Subscribe for real-time topic updates and unlimited access to our intelligence platform.